Coronavirus (COVID-19) Discussion Thread

[numberwang]

curl-6 said:

numberwang said:

The leading 'Oxford' mRNA vaccine has been paused.

Severe illness (transverse myelitis) developed.
A leading coronavirus vaccine trial is on hold: scientists react

It failed in animal trials anyway.

"There was no difference in the amount of viral RNA detected from this site in the vaccinated monkeys as compared to the unvaccinated animals. Which is to say, all vaccinated animals were infected"
Doubts over Oxford vaccine as it fails to stop coronavirus in animal trials

2/3 have side effects like pain, fever, fatigue etc. Had to used with painkiller paracetamol to ease the side effects. 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext#

Just a routine check; it's been resumed: https://www.abc.net.au/news/2020-09-13/astrazeneca-oxford-university-resume-coronavirus-vaccine-trial/12658984 

Your third link even states "all participants had neutralizing activity" and Phase I and II human trial results have shown that it produces a "strong immune response" and "no serious adverse health effects": https://www.ox.ac.uk/news/2020-07-20-new-study-reveals-oxford-coronavirus-vaccine-produces-strong-immune-response

You are repeating their own marketing spin, not a reliable source. I am referencing the actual clinical outcome data and it is terrible. A vaccine that doesn't reduce infections and viral load has no way to increase herd immunity. Taking Vitamin D would likely give better immunity.

The clinical outcome of this vaccine:

71% fatigue

68% headaches

60% systemic muscle ache

61 malaise

51% feverish

18% fever over 38°C

Injecting painkillers to hide these symptoms for a vaccine is unacceptable. We are not talking about a rare medication for a last ditch effort to save someone but a vaccine that is supposed to be given to healthy people.

Fatigue was reported in the ChAdOx1 nCoV-19 group by 340 (70%) participants without paracetamol and 40 (71%) with paracetamol and in the MenACWY group by 227 (48%) participants without paracetamol and 26 (46%) with paracetamol, whereas headaches were reported in the ChAdOx1 nCoV-19 group by 331 (68%) participants without paracetamol and 34 (61%) with paracetamol and in the MenACWY group by 195 (41%) participants without paracetamol and 21 (37%) participants with paracetamol.

Other systemic adverse reactions were common in the ChAdOx1 nCoV-19 group: muscle ache (294 [60%] participants without paracetamol and 27 [48%] with paracetamol), malaise (296 [61%] and 27 [48%]), chills (272 [56%] and 15 [27%]); and feeling feverish (250 [51%] and 20 [36%]). In the of ChAdOx1 nCoV-19 group, 87 (18%) participants without paracetamol and nine (16%) participants with paracetamol reported a temperature of at least 38°C, and eight (2%) patients without paracetamol had a temperature of at least 39°C. In comparison, two (<1%) of those receiving MenACWY reported a fever of at least 38°C, none of whom were receiving prophylactic paracetamol

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext#%20